113 related articles for article (PubMed ID: 37979476)
21. Competing risk nomograms for nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A big-data, intelligence platform-based analysis.
Huang XD; Zhou GQ; Lv JW; Zhou HQ; Zhong CW; Wu CF; Zheng ZQ; He XJ; Peng L; Ma J; Sun Y
Radiother Oncol; 2018 Nov; 129(2):389-395. PubMed ID: 30270098
[TBL] [Abstract][Full Text] [Related]
22. Predictive Value of ERCC1 mRNA Level from Receiver-Operator Characteristic and Pretreatment EBV-DNA Virus Load in Stage II Nasopharyngeal Carcinoma Patients Receiving Intensity-Modulated Radiotherapy with Concurrent Cisplatin.
Hua L; Chen S; Wei M; Shen Y; Long J; Lin Z; Meng Y; Guo C; Huang H; Tu X; Yao M
Cancer Biother Radiopharm; 2022 Feb; 37(1):2-10. PubMed ID: 33764811
[No Abstract] [Full Text] [Related]
23. The prognostic value of the ratio of neutrophils to lymphocytes before and after intensity modulated radiotherapy for patients with nasopharyngeal carcinoma.
Liu J; Wei C; Tang H; Liu Y; Liu W; Lin C
Medicine (Baltimore); 2020 Jan; 99(2):e18545. PubMed ID: 31914029
[TBL] [Abstract][Full Text] [Related]
24. Prognostic value and predictive threshold of tumor volume for patients with locally advanced nasopharyngeal carcinoma receiving intensity-modulated radiotherapy.
He YX; Wang Y; Cao PF; Shen L; Zhao YJ; Zhang ZJ; Chen DM; Yang TB; Huang XQ; Qin Z; Dai YY; Shen LF
Chin J Cancer; 2016 Nov; 35(1):96. PubMed ID: 27852284
[TBL] [Abstract][Full Text] [Related]
25. Prognostic Correlations between ABO Blood Group and Pre-Treatment Plasma Epstein-Barr Virus DNA in Patients with Nasopharyngeal Carcinoma Receiving Intensity-Modulated Radiotherapy.
Peng H; Chen L; Li WF; Zhang Y; Liu LZ; Tian L; Lin AH; Sun Y; Ma J
PLoS One; 2016; 11(11):e0166194. PubMed ID: 27835689
[TBL] [Abstract][Full Text] [Related]
26. Toxicity Profiles and Survival Outcomes Among Patients With Nonmetastatic Nasopharyngeal Carcinoma Treated With Intensity-Modulated Proton Therapy vs Intensity-Modulated Radiation Therapy.
Li X; Kitpanit S; Lee A; Mah D; Sine K; Sherman EJ; Dunn LA; Michel LS; Fetten J; Zakeri K; Yu Y; Chen L; Kang JJ; Gelblum DY; McBride SM; Tsai CJ; Riaz N; Lee NY
JAMA Netw Open; 2021 Jun; 4(6):e2113205. PubMed ID: 34143193
[TBL] [Abstract][Full Text] [Related]
27. Analysis of Plasma EBV-DNA and Soluble Checkpoint Proteins in Nasopharyngeal Carcinoma Patients after Definitive Intensity-Modulated Radiotherapy.
Ruan Y; Hu W; Li W; Lu H; Gu H; Zhang Y; Zhu C; Chen Q
Biomed Res Int; 2019; 2019():3939720. PubMed ID: 31192256
[TBL] [Abstract][Full Text] [Related]
28. Elevated plasma fibrinogen level shows superior prognostic value than Epstein-Barr virus DNA load for stage IVA/B nasopharyngeal carcinoma patients in the intensity-modulated radiotherapy era.
Lan M; Chen C; Huang Y; Mao M; Han F; Liao J; Deng M; Duan Z; Zheng L; Wu S; Lu T; Jian Y
Oncotarget; 2016 Jul; 7(29):46242-46252. PubMed ID: 27323828
[TBL] [Abstract][Full Text] [Related]
29. Prognostic Value of Serum Epstein-Barr Virus Antibodies and Their Correlation with TNM Classification in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma.
Zhang WR; Du YY; Guo CY; Zhou HX; Lin JY; Meng XH; Mo HY; Luo DH
Cancer Res Treat; 2021 Oct; 53(4):991-1003. PubMed ID: 33494127
[TBL] [Abstract][Full Text] [Related]
30. PET/CT-guided dose-painting versus CT-based intensity modulated radiation therapy in locoregional advanced nasopharyngeal carcinoma.
Liu F; Xi XP; Wang H; Han YQ; Xiao F; Hu Y; He Q; Zhang L; Xiao Q; Liu L; Luo L; Li Y; Mo Y; Ma HZ
Radiat Oncol; 2017 Jan; 12(1):15. PubMed ID: 28587681
[TBL] [Abstract][Full Text] [Related]
31. Pretreatment prognostic factors of survival and late toxicities for patients with nasopharyngeal carcinoma treated by simultaneous integrated boost intensity-modulated radiotherapy.
Lin YH; Huang TL; Chien CY; Chen HC; Hsu HC; Huang EY; Wang CJ; Huang YJ; Wang YM; Huang CC; Chou SY; Liao KC; Fang FM
Radiat Oncol; 2018 Mar; 13(1):45. PubMed ID: 29554940
[TBL] [Abstract][Full Text] [Related]
32. Prognostic value of total tumor volume in patients with nasopharyngeal carcinoma treated with intensity-modulated radiotherapy.
Liang SB; Teng JJ; Hu XF; Yang XL; Luo M; Fang XN; Liu DS; Chen Y; Fu LW
BMC Cancer; 2017 Jul; 17(1):506. PubMed ID: 28754109
[TBL] [Abstract][Full Text] [Related]
33. 10-Year Results of Therapeutic Ratio by Intensity-Modulated Radiotherapy Versus Two-Dimensional Radiotherapy in Patients with Nasopharyngeal Carcinoma.
Chen L; Zhang Y; Lai SZ; Li WF; Hu WH; Sun R; Liu LZ; Zhang F; Peng H; Du XJ; Lin AH; Sun Y; Ma J
Oncologist; 2019 Jan; 24(1):e38-e45. PubMed ID: 30082487
[TBL] [Abstract][Full Text] [Related]
34. Uncovering nasopharyngeal carcinoma from chronic rhinosinusitis and healthy subjects using routine medical tests via machine learning.
Liu Q; Du J; Li Y; Peng G; Wang X; Zhong Y; Du R
PLoS One; 2022; 17(9):e0274263. PubMed ID: 36083977
[TBL] [Abstract][Full Text] [Related]
35. Normal tissue complication probability (NTCP) models for predicting temporal lobe injury after intensity-modulated radiotherapy in nasopharyngeal carcinoma: A large registry-based retrospective study from China.
Wen DW; Lin L; Mao YP; Chen CY; Chen FP; Wu CF; Huang XD; Li ZX; Xu SS; Kou J; Yang XL; Ma J; Sun Y; Zhou GQ
Radiother Oncol; 2021 Apr; 157():99-105. PubMed ID: 33484752
[TBL] [Abstract][Full Text] [Related]
36. Dosimetric predictors of temporal lobe injury after intensity-modulated radiotherapy for T4 nasopharyngeal carcinoma: a competing risk study.
Huang J; Kong FF; Oei RW; Zhai RP; Hu CS; Ying HM
Radiat Oncol; 2019 Feb; 14(1):31. PubMed ID: 30736809
[TBL] [Abstract][Full Text] [Related]
37. Selection and validation of chemotherapy beneficiaries among elderly nasopharyngeal carcinoma (NPC) patients treated with intensity-modulated radiation therapy (IMRT): a large real-world study.
Wu YL; Yang KB; Huang Y; Shi JR; He QS; Chen L; Li WF; Huang XD; Lin L; Chen YP; Mao YP; Tang LL; Ma J
Radiat Oncol; 2022 Aug; 17(1):138. PubMed ID: 35941674
[TBL] [Abstract][Full Text] [Related]
38. Prognostic efficacy of combining tumor volume with Epstein-Barr virus DNA in patients treated with intensity-modulated radiotherapy for nasopharyngeal carcinoma.
Lu L; Li J; Zhao C; Xue W; Han F; Tao T; Chang H; Jia W; Lu T
Oral Oncol; 2016 Sep; 60():18-24. PubMed ID: 27531868
[TBL] [Abstract][Full Text] [Related]
39. Intensity-modulated radiotherapy prolongs the survival of patients with nasopharyngeal carcinoma compared with conventional two-dimensional radiotherapy: A 10-year experience with a large cohort and long follow-up.
Zhang MX; Li J; Shen GP; Zou X; Xu JJ; Jiang R; You R; Hua YJ; Sun Y; Ma J; Hong MH; Chen MY
Eur J Cancer; 2015 Nov; 51(17):2587-95. PubMed ID: 26318726
[TBL] [Abstract][Full Text] [Related]
40. Assessment of Survival Model Performance Following Inclusion of Epstein-Barr Virus DNA Status in Conventional TNM Staging Groups in Epstein-Barr Virus-Related Nasopharyngeal Carcinoma.
Li WZ; Wu HJ; Lv SH; Hu XF; Liang H; Liu GY; Lu N; Bei WX; Lv X; Guo X; Xia WX; Xiang YQ
JAMA Netw Open; 2021 Sep; 4(9):e2124721. PubMed ID: 34554238
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]